Latest quarter
AbbVie reported Q2 FY2026 revenue of $17.0 billion, up 10.2% from $15.4 billion in Q2 FY2025. The company’s revenue of $17.0 billion was 1.07% above the $16.8 billion consensus. AbbVie reported adjusted EPS, as the consensus counts it, of $3.65, compared with the $3.64 consensus and 0.27% above it.
The filing says Skyrizi and Rinvoq net revenues each increased 24% from a year earlier, driven by market-share uptake and market growth across indications. AbbVie’s filing says Humira net revenues fell 36%, reflecting direct biosimilar competition following loss of exclusivity, while global Imbruvica revenues declined 29% because of unfavorable U.S. pricing, lower demand and lower collaboration revenue. The company reported a 74.7% gross margin and a 37.9% operating margin, compared with 71.8% and 31.7%, respectively, a year earlier. AbbVie reported free cash flow of $3.1 billion, compared with $4.9 billion in Q2 FY2025. The available materials do not provide AbbVie’s own Q2 FY2026 guidance outcome.
| Q2 FY2026 | Q2 FY2025 | Change | |
|---|---|---|---|
| Revenue | $17.0 billion | $15.4 billion | 10.2% |
| Diluted EPS | $2.03 | $0.52 | 290.4% |
| Gross margin | 74.7% | 71.8% | 2.9 percentage points |
| Operating margin | 37.9% | 31.7% | 6.1 percentage points |
| Free cash flow | $3.1 billion | $4.9 billion | −36.2% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $3.65 | $3.64 | In line |
| Revenue | $17.0 billion | $16.8 billion | Beat by 1.07% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
No record of AbbVie’s latest earnings call was available. Consequently, the available materials do not provide call commentary from named executives on demand, pricing, margins, investment, competition, the quarter ahead, analyst questions or management responses.
Guidance
AbbVie’s management guidance was not available in the provided materials. Accordingly, the available materials do not identify changes from the company’s previous guidance or guidance that AbbVie stopped providing.